Niagen Bioscience, Inc. (NAGE) - What Are Researchers Saying About This Stock?

Key Points

• Analysts are broadly bullish: Five analysts give Niagen Bioscience an average “Buy” rating, including three Buys and one Strong Buy, with an average 12-month price target of $10.33.
• Institutional ownership has increased: Several funds recently initiated or expanded positions, and institutional investors collectively own 15.41% of the company.
• Shares remain near their 12-month low: NAGE opened at $2.49 versus a $2.46–$7.95 yearly range. The latest quarter met EPS expectations at $0.01, while revenue of $29.78 million fell slightly short of the $29.95 million consensus.

Shares of Niagen Bioscience, Inc. (NASDAQ:NAGE - Get Free Report) have been given an average recommendation of "Buy" by the five analysts that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation, three have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $10.33.

Several research analysts have recently weighed in on NAGE shares. HC Wainwright restated a "buy" rating on shares of Niagen Bioscience in a research note on Wednesday, July 1st. Roth Capital reaffirmed a "buy" rating on shares of Niagen Bioscience in a report on Wednesday, August 5th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Niagen Bioscience in a research report on Thursday. Finally, Freedom Capital upgraded Niagen Bioscience to a "strong-buy" rating in a report on Monday, July 6th.

Hedge Funds Weigh In On Niagen Bioscience

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. SteelPeak Wealth LLC purchased a new stake in shares of Niagen Bioscience during the 1st quarter valued at about $14,875,000. Arrowstreet Capital Limited Partnership raised its holdings in shares of Niagen Bioscience by 47.1% during the first quarter. Arrowstreet Capital Limited Partnership now owns 2,378,437 shares of the company's stock valued at $10,489,000 after purchasing an additional 761,685 shares during the last quarter. Tieton Capital Management LLC bought a new position in Niagen Bioscience during the second quarter valued at approximately $6,407,000. Renaissance Technologies LLC lifted its position in Niagen Bioscience by 45.4% during the first quarter. Renaissance Technologies LLC now owns 1,328,843 shares of the company's stock valued at $5,860,000 after purchasing an additional 414,725 shares during the period. Finally, Dimensional Fund Advisors LP lifted its position in Niagen Bioscience by 16.4% during the first quarter. Dimensional Fund Advisors LP now owns 1,071,133 shares of the company's stock valued at $4,723,000 after purchasing an additional 150,763 shares during the period. Institutional investors own 15.41% of the company's stock.

Niagen Bioscience Price Performance

Shares of NAGE opened at $2.49 on Monday. Niagen Bioscience has a twelve month low of $2.46 and a twelve month high of $7.95. The company has a market capitalization of $198.30 million, a P/E ratio of 13.83 and a beta of 2.02. The firm has a 50 day moving average of $2.98 and a 200 day moving average of $3.52.

Niagen Bioscience (NASDAQ:NAGE - Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported $0.01 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.01. Niagen Bioscience had a return on equity of 17.95% and a net margin of 12.39%. The business had revenue of $29.78 million for the quarter, compared to analysts' expectations of $29.95 million. On average, sell-side analysts expect that Niagen Bioscience will post 0.10 EPS for the current year.

About Niagen Bioscience

Niagen Bioscience, Inc is a life sciences company focused on products and technologies designed to support healthy aging and cellular health. The company's principal technology is nicotinamide riboside (NR), a form of vitamin B3 that serves as a precursor to nicotinamide adenine dinucleotide (NAD+), a coenzyme involved in cellular energy production and other biological processes.

The company develops and commercializes NIAGEN-branded NR ingredients for use in dietary supplements, functional foods and beverages, and other consumer health products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.